Pavan K. (Tem) Bendapudi, MD
Assistant Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
3 Blackfan Circle, Room 906, Boston MA 02215
Tel: 617-735-4252 FAX:617-735-4000
Dr. Bendapudi completed his undergraduate degree in biochemistry at Harvard College and received his medical degree from Stanford University, where he was a Howard Hughes Medical Institute research fellow in the laboratory of Dr. Dean Felsher. He subsequently pursued training in internal medicine at Massachusetts General Hospital, followed by fellowships in hematology, medical oncology, and transfusion medicine. Dr. Bendapudi continues to be clinically active in both hematology and transfusion medicine. He first joined the Division of Hemostasis and Thrombosis as a postdoctoral fellow in Dr. Flaumenhaft’s laboratory. Dr. Bendapudi holds academic appointments at Beth Israel Deaconess Medical Center, Massachusetts General Hospital, and the Broad Institute of Harvard and MIT.
Dr. Bendapudi’s laboratory is focused on the biology of humoral coagulation factors and takes a translational approach to studying the mechanism underlying hemostatic and thrombotic disease as it pertains to patient care. A central project in his laboratory is focused on the mechanism by which factor 12 (FXII) participates in coagulation, with an emphasis on the recruitment, activation, and propagation of FXII at sites of vascular injury and thrombus formation.
Dr. Bendapudi’s group also studies the functional genomics of purpura fulminans (PF), a rare, highly thrombotic subtype of disseminated intravascular coagulation seen in patients with sepsis. Whole exome sequencing of PF patients by Dr. Bendapudi’s group has implicated rare, inherited defects of the complement system in the development of PF and sepsis coagulopathy. Ongoing studies are focused on the genetic risk stratification of patients with sepsis and the development of drugs to target dysregulated innate immunity.
In addition to his basic research, Dr. Bendapudi serves as co-principal investigator of the Harvard Thrombotic Microangiopathies Research Collaborative, an interdisciplinary, multi-institutional project to study Thrombotic Thrombocytopenic Purpura (TTP) and allied disorders. His group has described one of the world’s largest experiences in TTP and developed the PLASMIC clinical prediction tool for rapid diagnosis of TTP.
Current and Recent Grants
NIH 1R03 HL162761 (PI, Bendapudi)
(Beth Israel Deaconess Medical Center/Harvard Medical School.)
“Antithrombotic Mechanisms of Protein Disulfide Isomerase Inhibition in vivo.”
NIH 1R21 HL153655 (PI, Bendapudi)
Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research (Beth Israel Deaconess Medical Center/Harvard Medical School.)
“Elucidating the Role of Inherited Complement System Defects in the Molecular Pathophysiology of Sepsis and Purpura Fulminans.”
Broad Institute/Novo Ventures Greenhouse Collaborative (PI, Bendapudi)
“Targeting Factor XII in Thrombosis and Hemostasis.” (Beth Israel Deaconess Medical Center).
The goal of this project is to identify methods to screen for small molecule inhibitors of factor XII and to validate novel indications for factor XII inhibition.
NIH 1K08 HL13684001 (PI, Bendapudi)
Mentored Clinical Scientist Research Career Development Award (Beth Israel Deaconess Medical Center/Harvard Medical School).
“The Role of Coagulation Factor XII in Hemostasis and Thrombosis.”
The goal of this project is to understand the mechanisms by which factor XII is recruited, activated, and propagated at sites of thrombus formation.
NIH U54 HL112302 (PI, Furie)
NHLBI Thrombosis-Hemostasis Scholar (Beth Israel Deaconess Medical Center/Harvard Medical School). “Identification and Characterization of Novel Antithrombotic PDI Inhibitors.”
National Hemophilia Foundation (PI, Bendapudi)
NHF-Baxter Clinical Fellowship (Boston Hemophilia Center).
Hemostasis and Thrombosis Research Society (PI, Bendapudi)
Mentored Research Award (Beth Israel Deaconess Medical Center/Harvard Medical School). “Antithrombotic Mechanisms of Protein Disulfide Isomerase Inhibition in vivo.”